Audited Results (Standalone and Consolidated) of the Company for the Quarter and Financial Year ended 30.05.2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.1 pts less than Nifty Microcap 250 and 1.7 pts less than its Healthcare Services peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Jeevan Scientific Technology reported FY25 standalone revenue from operations of ₹4,360.99 lakhs, up about 13% from ₹3,850.17 lakhs in FY24, and consolidated revenue of ₹4,684.36 lakhs versus ₹3,965.04 lakhs (up ~18%). The company swung back to profitability, posting standalone profit after tax of ₹73.57 lakhs compared to a loss of ₹104.96 lakhs in FY24, and a small consolidated profit of ₹5.90 lakhs versus a loss of ₹132.72 lakhs. However, the Q4 standalone result was a loss of ₹133.71 lakhs (vs loss of ₹73.68 lakhs in Q4 FY24), showing weakness in the final quarter even as the full year improved. Statutory auditor Pavuluri & Co. issued an unmodified (unqualified) opinion on both standalone and consolidated results. Non-current borrowings rose sharply (standalone from ₹177.21 lakhs to ₹602.21 lakhs), and cash balances dipped, though operating cash flow stayed positive.
Turnaround from loss to profit at the full-year level is a positive signal for shareholders, but the widening Q4 loss and rising debt warrant caution. Investors should watch whether the profit recovery sustains and how the increased borrowings are deployed.